Troubling Allegations in Risperdal Trial
Posted on: March 14, 2016 Risperdal
The most troubling aspect of a recent case decided against Johnson & Johnson (J&J) concerning its antipsychotic drug Risperdal is the allegation that the company deliberately withheld data from the U.S. Food and Drug Administration. An expert witness testified that J&J knew about the risk of gynecomastia associated with Risperdal but failed to show the complete extent to which young people may develop it when using the drug. This is troubling because it appears to be proof that the company is putting its bottom line ahead of the health and wellbeing of our country’s children. Apparently J&J decided its revenues were more important than the psychological trauma suffered by young men who took Risperdal and had their lives turned upside down when they began to develop breasts. These companies should be held liable for their actions and it was good to see a Philadelphia jury decide accordingly.
For more information on Risperdal and gynecomastia, visit our Risperdal lawsuit page.